In short
A groundbreaking clinical trial is underway to assess the potential of PD01B, a novel vaccine developed for patients with early-stage Parkinson's disease. This Phase 2 study aims to investigate the safety, tolerability, and effectiveness of PD01B in slowing the progression of this neurodegenerative disorder. The trial involves multiple centers and employs a double-blind, randomized, and placebo-controlled approach to ensure reliable results.
At a glance
- Study Type
- Phase 2, double-blind, randomized, placebo-controlled, multicenter
- Drug Name
- PD01B (ACI-7104.056)
- Target Condition
- Early-stage Parkinson's Disease
- Main Objectives
- Safety, tolerability, immunogenicity, pharmacodynamic effects
- Dosage
- Maximum 75 μg per injection, 6 injections over 74 weeks
- Key Eligibility
- Ages 40-75, early PD diagnosis, stable L-Dopa treatment
- Primary Endpoints
- Adverse events, antibody response
- Secondary Endpoints
- Alpha-synuclein biomarkers, DaT-SPECT changes, MDS-UPDRS scores
- Study Duration
- Approximately 100 weeks, with 108-week safety follow-up
What is PD01B?
PD01B, also known as ACI-7104.056, is a new experimental treatment being developed for people with early-stage Parkinson's disease. It is a type of medicine called a vaccine, but unlike vaccines that prevent diseases, PD01B is designed to treat an existing condition.
How Does PD01B Work?
PD01B targets a protein in the brain called alpha-synuclein. In Parkinson's disease, this protein can clump together and cause problems for brain cells. The vaccine is designed to help the body's immune system recognize and potentially reduce these harmful protein clumps.
Current Research on PD01B
Scientists are currently conducting a Phase 2 clinical trial to study PD01B. This research aims to:
- Check if PD01B is safe and well-tolerated by patients
- See how the body's immune system responds to the vaccine
- Measure the effect of PD01B on alpha-synuclein levels in the blood and spinal fluid
- Examine changes in brain scans (called DaT-SPECT) that show Parkinson's disease activity
- Assess if PD01B improves movement symptoms using a standard Parkinson's rating scale
Who Can Participate in the PD01B Study?
The study is looking for people who:
- Have been diagnosed with early-stage Parkinson's disease within the last 2 years
- Are between 40 and 75 years old
- Are taking a stable dose of levodopa (a common Parkinson's medication)
- Have mild symptoms (Hoehn-Yahr Stage I to II, which means symptoms on one or both sides of the body but still good balance)
There are also several factors that would prevent someone from participating, such as having other neurological conditions or a history of certain medical issues.
Study Details
The study is designed as follows:
- Participants will receive either PD01B or a placebo (a harmless substance with no active ingredients)
- The vaccine is given as an injection into the muscle
- Participants will receive 6 injections over 74 weeks (about 1.5 years)
- The maximum dose of PD01B in a single injection is 75 micrograms
- Neither the participants nor the researchers will know who is receiving PD01B or the placebo until the study is complete
Potential Benefits of PD01B
While it's too early to know for sure, researchers hope that PD01B might:
- Slow down the progression of Parkinson's disease
- Improve movement symptoms
- Provide a new treatment option for people with early-stage Parkinson's
Safety Considerations
The study is closely monitoring the safety of PD01B. This includes:
- Tracking any side effects or adverse events
- Regular physical and neurological examinations
- Brain scans to check for any changes
- Blood and urine tests
- Monitoring for any mood changes or suicidal thoughts
It's important to note that PD01B is still in the research phase. While early results are promising, more studies are needed to fully understand its effectiveness and safety for treating Parkinson's disease.